Orexigen Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:

The 16th Annual BIO CEO & Investor Conference

Date:

Tuesday, February 11, 2014

Time:

2:30 p.m. Eastern Time

Location:

The Waldorf Astoria, New York



 

2014 Leerink Swann Global Healthcare Conference

Date:

Thursday, February 13, 2014

Time:

1:00 p.m. Eastern Time

Location:

The Waldorf Astoria, New York

Both presentations will be webcast live. To access a webcast, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for Contrave is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize Contrave in the United States. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Denise Powell

VP, Corporate Communications and Business Development

BrewLife

(858) 875-8629

(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.



RELATED LINKS
http://www.orexigen.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.